Personalized briefing
Discovery of the day · Neurology
Antiseizure medication use in pregnancy and the risk of poor fetal growth in the EURAP international registry: a prospective cohort study
Dear Damien Boorman, this is your personalized scientific intelligence briefing — curated for your work in Neurology.
Key finding
Medicine · Neurology
Discovery of the day
Data from the EURAP international registry demonstrate that poor fetal growth is a significant adverse outcome of prenatal antiseizure medication exposure. The risk of poor fetal growth varies across individual monotherapies and specific drug combinations, and it increases with the number of concomitant antiseizure medications. These findings provide critical evidence for improving preconception counselling and risk prediction, enabling more individualized treatment selection that directly aligns with your goal of using neuroscience research to improve patient well-being.
Novelty
88%
Rigor
94%
Significance
86%
Validity
91%
Clarity
89%
Advertisement
GroupRFQ — join group deals on lab & medical equipment. Pool orders, unlock volume pricing. See open deals →
Your briefing is personalized based on your selected fields, keywords, and research interests.
